Arcus Biosciences, Inc. (NYSE:RCUS) Shares Sold by Decheng Capital LLC

Decheng Capital LLC trimmed its position in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 7.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 808,789 shares of the company's stock after selling 61,001 shares during the period. Arcus Biosciences comprises 2.6% of Decheng Capital LLC's portfolio, making the stock its 6th biggest holding. Decheng Capital LLC owned about 0.88% of Arcus Biosciences worth $12,043,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. Gilead Sciences Inc. bought a new stake in Arcus Biosciences during the 4th quarter valued at approximately $447,610,000. Adage Capital Partners GP L.L.C. bought a new position in shares of Arcus Biosciences during the 4th quarter valued at approximately $6,596,000. Trexquant Investment LP increased its position in Arcus Biosciences by 241.5% in the fourth quarter. Trexquant Investment LP now owns 300,548 shares of the company's stock worth $4,475,000 after purchasing an additional 212,552 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Arcus Biosciences by 11.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,702,302 shares of the company's stock valued at $25,348,000 after purchasing an additional 178,351 shares during the last quarter. Finally, Diadema Partners LP bought a new position in Arcus Biosciences during the fourth quarter valued at $2,471,000. Institutional investors own 92.89% of the company's stock.

Analyst Ratings Changes

RCUS has been the subject of several research reports. Barclays lowered their price objective on shares of Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating for the company in a research report on Wednesday, April 23rd. Bank of America reduced their target price on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 19th. HC Wainwright raised shares of Arcus Biosciences from a "neutral" rating to a "buy" rating and increased their target price for the company from $18.00 to $24.00 in a research note on Wednesday, February 26th. Finally, Morgan Stanley reduced their target price on shares of Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 18th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Arcus Biosciences has a consensus rating of "Buy" and a consensus target price of $28.38.

Arcus Biosciences Stock Down 3.0 %

Shares of NYSE:RCUS traded down $0.26 during trading on Thursday, reaching $8.49. The stock had a trading volume of 384,977 shares, compared to its average volume of 1,039,106. Arcus Biosciences, Inc. has a one year low of $6.50 and a one year high of $18.98. The company has a market capitalization of $892.62 million, a P/E ratio of -2.70 and a beta of 1.54. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08. The firm's 50-day simple moving average is $8.63 and its 200 day simple moving average is $12.87.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($1.03) EPS for the quarter, topping analysts' consensus estimates of ($1.17) by $0.14. The company had revenue of $36.00 million during the quarter, compared to analysts' expectations of $29.38 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. As a group, research analysts expect that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Yasunori Kaneko purchased 20,000 shares of the business's stock in a transaction on Thursday, February 27th. The shares were bought at an average cost of $10.06 per share, with a total value of $201,200.00. Following the transaction, the director now owns 28,400 shares of the company's stock, valued at approximately $285,704. This trade represents a 238.10 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Terry J. Rosen purchased 19,800 shares of the business's stock in a transaction on Thursday, February 27th. The shares were bought at an average cost of $10.18 per share, for a total transaction of $201,564.00. Following the completion of the transaction, the chief executive officer now directly owns 2,554,160 shares in the company, valued at $26,001,348.80. This trade represents a 0.78 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is owned by company insiders.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.